ongoing data from the phase 3 response trial of ruxolitinib for polycythemia vera
Published 9 years ago • 142 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
1:54
ongoing trials in polycythemia vera: low-pv & verify
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
3:06
results from the majic-pv trial: ruxolitinib vs bat for hydroxyurea resistant/intolerant pv
-
5:40
data from the phase 3 cassiopeia trial: d-vtd vs. vtd
-
59:05
regulation of growth by the mtor pathway
-
9:44
an update on the quantum-first trial: quizartinib plus chemotherapy in flt3-mutated aml
-
5:01
hodgkin lymphoma staging: from diagnosis to prognosis | the patient story
-
1:56
rationale for verify: rusfertide added to ongoing therapy in patients with polycythemia vera
-
1:23
response-2 5-year follow-up update: ruxolitinib vs bat in polycythemia vera without splenomegaly
-
2:09
majic update: promising results for ruxolitinib in pv and et
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
2:49
the 5-year update on the comfort-ii clinical trial of ruxolitinib
-
0:47
overview of the phase iii enhance trial schema
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
2:01
updated follow-up results of the phase iii gaia/cll13 trial
-
0:45
difference between quality of life & patient-reported outcomes
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
1:54
a novel clinical trial endpoint for acute gvhd